Search
01/03/2024
Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion
Casademont, EB, Molina, JM. Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion. Angiologia. 2024; 76(2)DOI:10.20960/angiologia.00496. PMID:. IF:(Q/D).
01/03/2024
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).
01/03/2024
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).
01/03/2024
What About Variant Histologies in Bladder Cancer?
Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).
01/03/2024
Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
Arqueros, C, Gallardo, A, Vidal, S, Osuna-Gómez, R, Tibau, A, Bell, OL, Cajal, T, Lerma, E, Lobato-Delgado, B, Salazar, J, Barnadas, A. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(5)DOI:10.3390/ijms25052627. PMID:38473874. IF:4.900(Q1/3D).
01/03/2024
A Clinicopathologic and Immunohistochemical Analysis of 46 Uterine Mesenchymal Tumors Including Conventional Adenosarcomas, Atypical Uterine Polyps and Other Related Sarcomas
Angelo, ED, Espinosa, I, Wang, AH, Kingsley, L, Nasr, S, Zdravkovic, S, Howitt, B, Prat, J. A Clinicopathologic and Immunohistochemical Analysis of 46 Uterine Mesenchymal Tumors Including Conventional Adenosarcomas, Atypical Uterine Polyps and Other Related Sarcomas. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).